LMWF5A suppresses cytokine release by modulating select inflammatory transcription factor activity in stimulated PBMC
- PDF / 2,475,589 Bytes
- 15 Pages / 595.276 x 790.866 pts Page_size
- 115 Downloads / 138 Views
Journal of Translational Medicine Open Access
RESEARCH
LMWF5A suppresses cytokine release by modulating select inflammatory transcription factor activity in stimulated PBMC Gregory Thomas1, Elizabeth Frederick1, Lisa Thompson1, Raphael Bar‑Or1,2,3,4,5, Yetti Mulugeta1, Melissa Hausburg2,3,4,5, Michael Roshon4, Charles Mains5 and David Bar‑Or2,3,4,5,6*
Abstract Background: Dysregulation of transcription and cytokine expression has been implicated in the pathogenesis of a variety inflammatory diseases. The resulting imbalance between inflammatory and resolving transcriptional programs can cause an overabundance of pro-inflammatory, classically activated macrophage type 1 (M1) and/or helper T cell type 1 (Th1) products, such as IFNγ, TNFα, IL1-β, and IL12, that prevent immune switching to resolution and healing. The low molecular weight fraction of human serum albumin (LMWF5A) is a novel biologic drug that is currently under clinical investigation for the treatment of osteoarthritis and the hyper-inflammatory response associated with COVID19. This study aims to elucidate transcriptional mechanisms of action involved with the ability of LMWF5A to reduce pro-inflammatory cytokine release. Methods: ELISA arrays were used to identify cytokines and chemokines influenced by LMWF5A treatment of LPSstimulated peripheral blood mononuclear cells (PBMC). The resulting profiles were analyzed by gene enrichment to gain mechanistic insight into the biologic processes and transcription factors (TFs) underlying the identified differ‑ entially expressed cytokines. DNA-binding ELISAs, luciferase reporter assays, and TNFα or IL-1β relative potency were then employed to confirm the involvement of enriched pathways and TFs. Results: LMWF5A was found to significantly inhibit a distinct set of pro-inflammatory cytokines (TNFα, IL-1β, IL-12, CXCL9, CXCL10, and CXCL11) associated with pro-inflammatory M1/Th1 immune profiles. Gene enrichment analysis also suggests these cytokines are, in part, regulated by NF-κB and STAT transcription factors. Data from DNA-binding and reporter assays support this with LMWF5A inhibition of STAT1α DNA-binding activity as well as a reduction in overall NF-κB-driven luciferase expression. Experiments using antagonists specific for the immunomodulatory and NF-κB/STAT-repressing transcription factors, peroxisome proliferator-activated receptor (PPAR)γ and aryl hydrocarbon receptor (AhR), indicate these pathways are involved in the LMWF5A mechanisms of action by reducing LMWF5A drug potency as measured by TNFα and IL-1β release. Conclusion: In this report, we provide evidence that LMWF5A reduces pro-inflammatory cytokine release by activat‑ ing the immunoregulatory transcription factors PPARγ and AhR. In addition, our data indicate that LMWF5A sup‑ presses NF-κB and STAT1α pro-inflammatory pathways. This suggests that LMWF5A acts through these mechanisms to decrease pro-inflammatory transcription factor activity and subsequent inflammatory cytokine production.
*Correspondence: [email protected] 2 Trauma Re
Data Loading...
